Biotechnology in Europe - Investing in the Future

The biotechnology sector is by its very nature a risky sector for investment. The sector is Research & Development intensive and heavily regulated, the cost of getting a product to market can be significant.
However, the rewards of transforming science into breakthrough solutions for today’s societal challenges can be enormous. This is particularly true in a world where challenges are international by nature: current or future pandemics, climate change and economic recovery. The current crisis is set to accelerate the adoption of new technologies like e-commerce, digital payments, remote working, and biotechnology innovations including genome editing. Yet, in biotechnology the longer pay back model may deter investors from pursuing innovations in favour of other sectors with shorter return on investment periods.
Despite major commitment at EU level, investment in the EU biotechnology industry remains significantly lower than in other areas of the world, such as China and the United States. This raises the question, whether Europe has the right regulatory frameworks and market conditions to attract investments in biotechnology & life sciences.

Join this exciting panel debate to hear of innovative biotech founders and public & private investors active in the European market, on how to leverage the EU biotech & life science market further.

Confirmed speakers:
- Ms Marisa Hernández Latorre, CEO, Ingelia SL
- Mr Cedric Ververken, CEO, Confo Therapeutics
- Ms Sandra Ferri, Head of Life Sciences Competence Center, EIF
- Dr Rainer Strohmenger, Managing Partner, Wellington Partners
This video conference is co-hosted by EuropaBio & Invest Europe and will be moderated by Bernard J Grimm EuropaBio and Eric De Montgolfier CEO of Invest Europe.
Online Event